ABCL

Over the past six months, AbCellera Biologics Inc.'s stock price has experienced a significant upward trend, increasing by 272.06%. Key events impacting the stock include the announcement of positive Phase 2 clinical trial results for ABCL635, its single-dose treatment for menopausal hot flashes, presented at the IMS World Congress on Menopause in September 2026, which contributed to a rise in shares. In August 2026, AbCellera announced and priced an oversubscribed $200 million public offering of common shares and pre-funded warrants, improving its financial position with over $630 million in liquidity and additional funding commitments. New partnership deals, including collaborations with Jazz Pharmaceuticals and Vertex Pharmaceuticals, have also positively impacted investor confidence and the stock. Goldman Sachs resumed coverage on AbCellera Biologics in September 2026 with a Neutral rating and a price target of $13.00. Despite a significant drop in revenue and an adjusted loss in the second quarter of 2026, the stock still saw gains due to other positive developments and a strong cash position.